Growth Metrics

RxSight (RXST) Other Non Operating Income (2023)

RxSight posted quarterly Other Non Operating Income of -$1.4 million for Q3 2023, down 288.67% on a QoQ basis from -$362000.0 in Q2 2023.

RxSight (RXST) has 1 years of Other Non Operating Income data on file, last reported at -$1.4 million in Q3 2023.

  • For the quarter ending Q3 2023, Other Non Operating Income changed N/A year-over-year to -$1.4 million; the trailing twelve-month figure through Sep 2024 stood at -$1.4 million (up 20.46% YoY), and the FY2023 full-year result was -$1.8 million, changed N/A from the prior year.
  • Other Non Operating Income for Q3 2023 stood at -$1.4 million, down from -$362000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at -$362000.0 in Q2 2023 and bottomed at -$1.4 million in Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 RxSight 215.82 Mn -2.06 Mn 23.50 Mn

Historic Data

Download Data 🔒
DateValue
Sep 30, 2023 -1.41 Mn
Jun 30, 2023 -362,000.00